1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Constriction, Pathologic in 3 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Constriction, Pathologic: The condition of an anatomical structure's being constricted beyond normal dimensions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epicardial coronary stenosis causes myocardial ischemia; however, the role of coronary microvessels is poorly understood in the pathogenesis of effort angina." | 2.73 | Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. ( Fukumoto, Y; Hirakawa, Y; Hirooka, Y; Inokuchi, K; Ito, A; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Q | 1 |
| Wang, J | 1 |
| Liu, F | 1 |
| Ma, W | 1 |
| Hu, H | 1 |
| Ran, C | 1 |
| Li, F | 1 |
| Pan, Q | 1 |
| Disli, OM | 1 |
| Ozdemir, E | 1 |
| Berkan, O | 1 |
| Bagcivan, I | 1 |
| Durmus, N | 1 |
| Parlak, A | 1 |
| Fukumoto, Y | 1 |
| Mohri, M | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Hirakawa, Y | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Takeshita, A | 1 |
| Shimokawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Constriction, Pathologic
| Article | Year |
|---|---|
Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Co | 2007 |
2 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Constriction, Pathologic
| Article | Year |
|---|---|
A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Biliary Tract Disease | 2018 |
Rho-kinase inhibitors Y-27632 and fasudil prevent agonist-induced vasospasm in human radial artery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Amides; Constriction, Pathologic; Dose-Response | 2009 |